IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2955
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$310K
Yong W. Hu
Bon Natural Life Limited engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$BON Bon Natural Life Ltd | 44 | 42 | 18 | 55 | - | - | -14.2% | -9.6% | 20.8% | -8.7% | -11.0% | -21.7% | 0.0% | 21.0x | $310K | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Bon Natural Life Ltd (BON) receives a "Reduce" rating with a composite score of 44.1/100. It ranks #2955 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Yong W. Hu
Chief Executive Officer
Labor Force
100
42
23
27
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for BON
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Average quality profile
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for BON.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 42 | 20 | +22ALPHA |
| MOMENTUM | 55 | 46 | +9ALPHA |
| VALUATION | 18 | 4 | +14ALPHA |
| INVESTMENT | 23 | 8 | +15ALPHA |
| STABILITY | 27 | 7 | +20ALPHA |
| SHORT INT | 84 | 93 | -9DRAG |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -15.3% vs WACC 6.2% (spread -21.4%)
GM 21% vs sector 43%, OM -9% vs sector 1%
Capital turnover 2.22x, R&D intensity 4.0%
Rev growth -22%, 5yr history
Interest coverage -4.4x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Bon Natural Life Ltd receives a Reduce rating from our analysis, with a composite score of 44.1/100 and 2 out of 5 stars, ranking #2955 out of 7,333 stocks. BON's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
BON's quality score of 42/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -14.2% (sector avg: -2.5%), gross margins of 20.8% (sector avg: 42.5%), net margins of -11.0% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
BON registers a value score of just 18/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 0.22x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Bon Natural Life Ltd's investment score of 23/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -21.7% vs. a sector average of 5.9% and a return on assets of -9.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
BON demonstrates moderate momentum with a score of 55/100, suggesting a neutral price trend without strong directional conviction. Revenue growth stands at -21.7% year-over-year, while a beta of 1.12 reflects its sensitivity to broader market moves. Moderate momentum may indicate the stock is consolidating or transitioning between trends, warranting close monitoring of upcoming catalysts.
BON's stability score of 27/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.12 and a debt-to-equity ratio of 21.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
BON's short interest factor score of 84/100 indicates very low short selling activity relative to peers — a positive signal suggesting institutional investors see limited near-term downside. Specific risk factors include elevated leverage (D/E: 21.00x), micro-cap liquidity risk. As a micro-cap company with a market capitalization of $309,704, Bon Natural Life Ltd benefits from the generally lower volatility and deeper liquidity associated with its size class.
Bon Natural Life Ltd is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2955 of 7,333 overall (60th percentile). Key comparisons include ROE of -14.2% trailing the -2.5% sector median and operating margins of -8.7% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While BON currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (18) would have the largest impact on the composite score.
ROE 474% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 51% BELOW SECTOR MEDIAN
Op. Margin 774% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Bon Natural Life Ltd (BON) as a Reduce with a composite score of 44.1/100 at a current price of $1.60. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (55th percentile) and quality (42th percentile), which together account for the majority of the composite score. Offsetting weakness in value (18th percentile) and investment (23th percentile) tempers our overall conviction. We assign a No Moat rating (24/100), High uncertainty, and Poor capital allocation.
Key items to watch: the path to profitability; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Bon Natural Life Ltd holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 44.1/100 places it at rank #2955 in our full 7,333-stock universe. At $309,704 in market capitalization, Bon Natural Life Ltd is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue contraction of -22% combined with momentum at the 55th percentile paints a cautious picture of the near-term business outlook. The market appears to be pricing in continued challenges, and a catalyst for reversal is not clearly visible from current data.
The margin cascade tells an important story: gross margins of 21% (-21.7pp vs sector) narrow to operating margins of -9% (-10.0pp vs sector) and net margins of -11.0%, yielding a gross-to-net conversion rate of -53%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.60, Bon Natural Life Ltd is trading at a premium to fundamental value. Our value factor score of 18/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 0.2x, P/S of 0.2x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
A conservative balance sheet (21% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Reduce rating (composite 44.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Revenue decline of -22% signals business deterioration — declining revenues make it difficult to grow into the current valuation and often precede further negative revisions.
Thin net margins of -11.0% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Elevated short interest (84th percentile) indicates that sophisticated market participants are betting against the stock.
We assign a High uncertainty rating to Bon Natural Life Ltd. Key risk factors include current negative profitability (net margin -11.0%), below-average price stability (27th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -11.0%); below-average price stability (27th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 27th percentile and quality factor at the 42th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: conservative leverage (21% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Bon Natural Life Ltd's capital allocation as Poor. Key concerns include low returns on equity (-14.2%), negative profitability, weak asset returns (ROA -9.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Bon Natural Life Ltd significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Bon Natural Life Ltd receives a Reduce rating with a composite score of 44.1/100 (rank #2955 of 7,333). Our quantitative framework assigns a No Moat (24/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on Bon Natural Life Ltd at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Bon Natural Life Ltd a meaningful economic moat, scoring 24/100 on our composite assessment. The ROIC-WACC spread of -21.4% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 7.7/20.
The strongest moat sources are margin superiority (7.7/20) and financial resilience (7.1/20). GM 21% vs sector 43%, OM -9% vs sector 1%. Interest coverage -4.4x. These pillars form the core of Bon Natural Life Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0.8/20) and growth durability (2.8/20). ROIC -15.3% vs WACC 6.2% (spread -21.4%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Bon Natural Life Ltd's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include declining revenues (-22%) that pressure the earnings outlook. The margin cascade from 21% gross to -9% operating to -11.0% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 42th percentile.
The margin profile shows gross margins of 21%, operating margins of -9%, net margins of -11.0%. Return metrics include ROE of -14.2% and ROA of -9.6%. Relative to the Manufacturing sector, gross margins are 21.7 percentage points below the sector median of 43%, and ROE of -14.2% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 21%, revenue growth of -22%. The sector median D/E is 0%, putting Bon Natural Life Ltd at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.

U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Investors will keep an eye on the Federal Reserve's decision on interest rates this week. Analysts say any de-escalation in trade tensions should be positive for the economy and financial markets.

U.S. stock futures were flat on Tuesday as investors remained cautious ahead of the FOMC meeting. Analysts say the only certainty is that 'things will remain uncertain for the time being'.
Bon Natural Life Limited (Nasdaq: BON) ("Bon" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, today announced the successful development of a premium anti-aging facial mask incorporating apple polyphenols as its core active ingredient and integrated with AI-enabled flexible bio-electronic technology. Leveraging advanced transdermal delivery systems, this product integrates plant-derived active ingredients with intelligent fl
Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Scien
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
Above 50MA
37.18%
Net New Highs
+51081